| Title |
Immune Checkpoint Blockade: The New Frontier in Cancer Treatment
|
|---|---|
| Published in |
Targeted Oncology, February 2018
|
| DOI | 10.1007/s11523-017-0549-7 |
| Pubmed ID | |
| Authors |
Jeffrey M. Clarke, Daniel J. George, Stacey Lisi, April K. S. Salama |
| Abstract |
Immune checkpoint blockers have revolutionized cancer treatment in recent years. These agents are now approved for the treatment of several malignancies, including melanoma, squamous and non-squamous non-small cell lung cancer, renal cell carcinoma, urothelial carcinoma, and head and neck squamous cell carcinoma. Studies have demonstrated the significant impact of immunotherapy versus standard of care on patient outcomes, including durable response and extended survival. The use of immunotherapy-based combination therapy has been shown to further extend duration of response and survival. Immunotherapies function through modulation of the immune system, which can lead to immune-mediated adverse events (imAEs). These include a range of dermatologic, gastrointestinal, endocrine, and hepatic toxicities, as well as other less common inflammatory events. ImAEs are typically low grade and manageable when identified early and treated with appropriate measures. Identifying the right patient for the right therapy will become more important as new immunotherapies and immunotherapy-based combinations are approved and costs of cancer care continue to rise. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 50 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 9 | 18% |
| Researcher | 8 | 16% |
| Student > Postgraduate | 7 | 14% |
| Other | 6 | 12% |
| Student > Bachelor | 4 | 8% |
| Other | 8 | 16% |
| Unknown | 8 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 38% |
| Biochemistry, Genetics and Molecular Biology | 8 | 16% |
| Agricultural and Biological Sciences | 5 | 10% |
| Immunology and Microbiology | 4 | 8% |
| Veterinary Science and Veterinary Medicine | 1 | 2% |
| Other | 3 | 6% |
| Unknown | 10 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 February 2018.
All research outputs
#15,492,327
of 23,023,224 outputs
Outputs from Targeted Oncology
#270
of 555 outputs
Outputs of similar age
#274,014
of 446,078 outputs
Outputs of similar age from Targeted Oncology
#9
of 15 outputs
Altmetric has tracked 23,023,224 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 555 research outputs from this source. They receive a mean Attention Score of 2.8. This one is in the 41st percentile – i.e., 41% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 446,078 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.